Spiro Isoquinoline Piperidine PRMT5 Inhibitors for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
PRMT5 is aberrantly expressed in various human cancers and plays a critical role in epigenetic regulation, leading to aberrant gene expression and poor prognosis, while its role in hemoglobinopathies like β-thalassemia and sickle cell disease involves silencing of fetal globin genes, necessitating targeted therapeutic strategies.
Innovation Solution
Development of 1,4-dihydro-2H-spiro[isoquinoline-3,4'-piperidine derivatives that inhibit PRMT5 activity, offering potential therapeutic compounds for cancer treatment by modulating gene expression and upregulating fetal globin gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 is inhibited, then cancer cell growth is suppressed and apoptosis is induced, but normal cellular functions may be disrupted
Solution Approach 1:
The patent employs prodrug activation where the inhibitor is converted to its active form specifically in cancer cells through enzymatic cleavage by esterases or cytochrome P450 enzymes. This localized activation ensures that PRMT5 inhibition occurs primarily in malignant cells rather than normal cells, thereby improving cancer treatment efficacy while minimizing off-target effects on healthy tissues
Solution Approach 2:
The patent introduces prodrug intermediates that serve as inactive precursors which are transported into cancer cells and then converted to active inhibitors by cellular enzymes. These intermediary compounds enable selective delivery of the active inhibitor to cancer cells, reducing exposure of normal cells to the harmful effects of PRMT5 inhibition
2Reliability
If PRMT5 inhibitors are developed for cancer therapy, then tumor growth is controlled, but drug delivery and bioavailability may be limited
Solution Approach 1:
The patent modifies the chemical parameters of PRMT5 inhibitors by introducing lipophilic groups, basic nitrogen atoms, and specific molecular weight ranges (150-500 Da) to optimize oral bioavailability. These parameter changes enhance membrane permeability and metabolic stability, thereby improving drug delivery and maintaining effective tumor growth control
Solution Approach 2:
The patent structures inhibitors as modular molecules with distinct functional segments: a core heterocyclic scaffold (isoquinoline, piperidine, pyrimidine), linkers, and terminal functional groups. This segmentation allows optimization of each component for specific properties such as binding affinity, solubility, and metabolic stability, collectively improving drug delivery while maintaining anti-tumor efficacy
3Reliability
If PRMT5 inhibitors are used to treat hemoglobinopathies, then fetal globin gene expression is upregulated, but the mechanism of action is complex and not fully understood
Solution Approach 1:
The patent isolates and targets the specific epigenetic mechanism involving PRMT5-mediated histone H3 arginine methylation that regulates fetal globin gene silencing. By extracting and inhibiting this specific molecular interaction, the complex downstream effects on chromatin structure and gene expression are simplified into a single targetable pathway, thereby reliably upregulating fetal globin expression while reducing mechanistic complexity
Data Source
AI summary
The present invention provides a compound of Formula (I) (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.